Filtered By:
Therapy: Neoadjuvant Therapy
This page shows you your search results in order of date. This is page number 4.
Order by Relevance | Date
Total 9982 results found since Jan 2013.
Naples score: a novel prognostic biomarker for breast cancer patients undergoing neoadjuvant chemotherapy
CONCLUSIONS: In breast cancer patients who have undergone NAC, NPS is a novel prognostic indicator. NPS combined with clinicopathological features showed good predictive ability, and its performance was better than that of traditional pathological TNM staging.PMID:37698677 | DOI:10.1007/s00432-023-05366-x
Source: Clinical Breast Cancer - September 12, 2023 Category: Cancer & Oncology Authors: Yuting Xiu Cong Jiang Qinghua Huang Xiao Yu Kun Qiao Danping Wu Xiaotian Yang Shiyuan Zhang Xiangshi Lu Yuanxi Huang Source Type: research
Presentation of Gastrointestinal Stromal Tumor, Pancreatic Adenocarcinoma, and Gastric Adenocarcinoma in a Woman With No Identifiable Genetic Abnormalities
This report details the first known case of co-occurrence of gastrointestinal stromal tumor (GIST), pancreatic adenocarcinoma, and gastric adenocarcinoma in an individual with no identifiable genetic abnormalities. The patient is a 57-year-old female who presented with abdominal pain. CT scan demonstrated a pancreatic mass, and endoscopic ultrasound demonstrated an additional gastric mass. Biopsy of both masses demonstrated adenocarcinoma; however, the masses were found to have different origins. The patient underwent neoadjuvant chemotherapy with excellent response. She then underwent surgical intervention, which demonstr...
Source: The American Surgeon - September 12, 2023 Category: Surgery Authors: Catherine Read Marybeth Hughes Omar Itani Source Type: research
The Impact of COVID19 on Treatment Practices for Patients With Early Breast Cancer: A Cross-Sectional Study From a Large Cancer Center In Italy
CONCLUSIONS: There was no evidence for major changes in the management of patients with EBC during 2019-2021 and no treatment delays were observed. Our findings suggest that more women presented with palpable nodules at diagnosis, but the stage distribution did not change over time. Validation on a larger cohort of patients is warranted to robustly assess the impact of the COVID19 pandemic on treatment practices for patients with EBC.PMID:37699107 | DOI:10.1093/oncolo/oyad255
Source: The Oncologist - September 12, 2023 Category: Cancer & Oncology Authors: Fabio Girardi Sabrina Marini Francesca Porra Sonia Carpentieri Alberto Marchet Tania Saibene Marcello Lo Mele Tommaso Giarratano Carlo Alberto Giorgi Eleonora Mioranza Cristina Falci Giovanni Faggioni Francesca Caumo Gaia Griguolo Maria Vittoria Dieci Val Source Type: research
Long-course chemoradiation plus concurrent/sequential PD-1 blockade as neoadjuvant treatment for MMR-status-unscreened locally advanced rectal cancer: protocol of a multicentre, phase 2, randomised controlled trial (the POLAR-STAR trial)
BMJ Open. 2023 Sep 12;13(9):e069499. doi: 10.1136/bmjopen-2022-069499.ABSTRACTINTRODUCTION: Recent preclinical studies have discovered unique synergism between radiotherapy and immune checkpoint inhibitors, which has already brought significant survival benefit in lung cancer. In locally advanced rectal cancer (LARC), neoadjuvant radiotherapy plus immune checkpoint inhibitors have also achieved surprisingly high pathological complete response (pCR) rates even in proficient mismatch-repair patients. As existing researches are all phase 2, single-cohort trials, we aim to conduct a randomised, controlled trial to further clar...
Source: Cancer Control - September 12, 2023 Category: Cancer & Oncology Authors: Kai Pang Yun Yang Dan Tian Na Zeng Shun Cao Shen Ling Jiale Gao Pengfei Zhao Hao Wang Yuanyuan Kong Jie Zhang Guangyong Chen Wei Deng Zhigang Bai Lan Jin Guoju Wu Danyang Zhu Yue Wang Jiaolin Zhou Bin Wu Guole Lin Yi Xiao Zhidong Gao Yingjiang Ye Xin Wang Source Type: research
Nipple-Sparing Mastectomies in Patients over the Age of 60 Years: Factors Associated with Surgical Outcomes
CONCLUSIONS: Our data support NSM in patients over the age of 60 years with acceptable outcomes within the standard of care. Locoregional recurrence was within the cited range of 0-5%, and only diabetes and prior radiation were associated with reconstructive complications. NSM should thus be offered when appropriate regardless of increased age to achieve oncologic and reconstructive goals.PMID:37700172 | DOI:10.1245/s10434-023-14278-6
Source: Ann Oncol - September 12, 2023 Category: Cancer & Oncology Authors: Nisha Parmeshwar Catherine L Dugan Laura L Barnes Justin K Cheng Anne K Patterson Amanda Miller Rita Mukhtar Merisa Piper Source Type: research
Presentation of Gastrointestinal Stromal Tumor, Pancreatic Adenocarcinoma, and Gastric Adenocarcinoma in a Woman With No Identifiable Genetic Abnormalities
This report details the first known case of co-occurrence of gastrointestinal stromal tumor (GIST), pancreatic adenocarcinoma, and gastric adenocarcinoma in an individual with no identifiable genetic abnormalities. The patient is a 57-year-old female who presented with abdominal pain. CT scan demonstrated a pancreatic mass, and endoscopic ultrasound demonstrated an additional gastric mass. Biopsy of both masses demonstrated adenocarcinoma; however, the masses were found to have different origins. The patient underwent neoadjuvant chemotherapy with excellent response. She then underwent surgical intervention, which demonstr...
Source: The American Surgeon - September 12, 2023 Category: Surgery Authors: Catherine Read Marybeth Hughes Omar Itani Source Type: research
Predictive and Prognostic Role of Neutrophil to Lymphocyte Ratio in Rectal Cancer: A Case Control Study with Propensity Score Analysis
Conclusions: Overall, a pretherapeutic high NLR ( 2.58) was not found to predict survival or response do neoadjuvant therapy in patients with rectal cancer. However, a higher NLR may be associated with worse outcomes in advanced colorectal cancer.PMID:37698002 | DOI:10.21614/chirurgia.2023.v.118.i.4.p.399
Source: Cancer Control - September 12, 2023 Category: Cancer & Oncology Authors: Constantin Simiras Stefan Morarasu Delia-Maria Simiras Stefan Iacob Wee Liam Ong Ana Maria Musina Natalia Velenciuc Cristian Ene Roata Sorinel Lunca Gabriel-Mihail Dimofte Source Type: research
GRECCAR 14 - a multicentric, randomized, phase II-III study evaluating the tailored management of locally advanced rectal carcinoma after a favourable response to induction chemotherapy: study protocol
CONCLUSION: If GRECCAR 14 demonstrates the ability to tailor TNT for LARC, this could lead to changes in clinical practice.PMID:37697712 | DOI:10.1111/codi.16740
Source: Cancer Control - September 12, 2023 Category: Cancer & Oncology Authors: Philippe Rouanet Florence Castan Thibault Mazard Claire Lemanski Stephanie Nougaret Emmanuel Deshayes Patrick Chalbos Sophie Gourgou Christophe Taoum GRECCAR, PRODIGE study group Source Type: research
Naples score: a novel prognostic biomarker for breast cancer patients undergoing neoadjuvant chemotherapy
CONCLUSIONS: In breast cancer patients who have undergone NAC, NPS is a novel prognostic indicator. NPS combined with clinicopathological features showed good predictive ability, and its performance was better than that of traditional pathological TNM staging.PMID:37698677 | DOI:10.1007/s00432-023-05366-x
Source: Clinical Genitourinary Cancer - September 12, 2023 Category: Cancer & Oncology Authors: Yuting Xiu Cong Jiang Qinghua Huang Xiao Yu Kun Qiao Danping Wu Xiaotian Yang Shiyuan Zhang Xiangshi Lu Yuanxi Huang Source Type: research
The Impact of COVID19 on Treatment Practices for Patients With Early Breast Cancer: A Cross-Sectional Study From a Large Cancer Center In Italy
CONCLUSIONS: There was no evidence for major changes in the management of patients with EBC during 2019-2021 and no treatment delays were observed. Our findings suggest that more women presented with palpable nodules at diagnosis, but the stage distribution did not change over time. Validation on a larger cohort of patients is warranted to robustly assess the impact of the COVID19 pandemic on treatment practices for patients with EBC.PMID:37699107 | DOI:10.1093/oncolo/oyad255
Source: The Oncologist - September 12, 2023 Category: Cancer & Oncology Authors: Fabio Girardi Sabrina Marini Francesca Porra Sonia Carpentieri Alberto Marchet Tania Saibene Marcello Lo Mele Tommaso Giarratano Carlo Alberto Giorgi Eleonora Mioranza Cristina Falci Giovanni Faggioni Francesca Caumo Gaia Griguolo Maria Vittoria Dieci Val Source Type: research
Naples score: a novel prognostic biomarker for breast cancer patients undergoing neoadjuvant chemotherapy
CONCLUSIONS: In breast cancer patients who have undergone NAC, NPS is a novel prognostic indicator. NPS combined with clinicopathological features showed good predictive ability, and its performance was better than that of traditional pathological TNM staging.PMID:37698677 | DOI:10.1007/s00432-023-05366-x
Source: Clinical Genitourinary Cancer - September 12, 2023 Category: Cancer & Oncology Authors: Yuting Xiu Cong Jiang Qinghua Huang Xiao Yu Kun Qiao Danping Wu Xiaotian Yang Shiyuan Zhang Xiangshi Lu Yuanxi Huang Source Type: research
Neoadjuvant PD-1 inhibitor plus apatinib and chemotherapy versus apatinib plus chemotherapy versus chemotherapy alone in patients with locally advanced gastric cancer
This study aimed to evaluate this combination as a neoadjuvant therapy in locally advanced gastric cancer (LAGC). In this retrospective study, data from 179 LAGC patients who underwent neoadjuvant therapy with a PD-1 inhibitor plus apatinib and chemotherapy (PAC group, n=56), apatinib and chemotherapy (AC group, n=50), or chemotherapy alone (C group, n=73) were analyzed. The PAC group displayed a numerically higher radiologic objective response rate than the AC group (73.2% vs. 60.0%, P=0.149) and significantly higher than the C group (73.2% vs. 35.6%, P<0.001). Tumor resection rates between the PAC and AC groups were n...
Source: Cell Research - September 11, 2023 Category: Cytology Authors: Hui Xiong Yun Li Source Type: research
Clinical Utility of Pre-Therapeutic 18FFDG PET/CT Imaging for Predicting Outcomes in Breast Cancer
CONCLUSION: High TMTV in pre-therapeutic imaging is associated with no-pCR and recurrence. It can help in identifying high-risk patients and be considered as an intensified or alternative adjuvant therapy for closely monitoring patients.PMID:37685551 | DOI:10.3390/jcm12175487
Source: Clinical Breast Cancer - September 9, 2023 Category: Cancer & Oncology Authors: Sophia Najid Romain-David Seban Laurence Champion Alexandre De Moura Clara Sebbag H élène Salaün Luc Cabel Claire Bonneau Source Type: research
